Palmitoylethanolamide (PEA) is a fatty acid amide compound the body produces. It influences the endocannabinoid system without binding cannabinoid receptors directly, instead activating the PPAR-α nuclear receptor to drive anti-inflammatory, pain-modulating, and neuroprotective effects. Used clinically since the 1990s for neuropathic and chronic pain, with recent expansion into stress, sleep, and immunity.

How do HRV and SDNN relate to the autonomic nervous system?

Heart rate variability (HRV) measures variation in beat-to-beat intervals, reflecting the parasympathetic-sympathetic balance of the autonomic nervous system. SDNN (Standard Deviation of Normal-to-Normal intervals) is the standard deviation of intervals over 24 hours or a defined window, serving as a composite indicator of overall autonomic activity. Higher SDNN correlates with stronger stress resilience.

Is Levagen+ available in Korea?

Levagen+ is Australian Gencor's PEA branded ingredient. In Korea, standalone PEA supplements are classified as general dietary supplements rather than MFDS-certified health functional foods, available via direct import or select supplement specialty stores. Monthly cost runs 40,000-70,000 KRW for direct import. Pharmaceutical-grade PEA used in pain medicine requires prescription.

PEA 600mg over 6 Weeks Lifted SDNN by 9.7ms in Stressed Female Students

Can a dietary supplement meaningfully shift heart rate variability, the standard marker of autonomic stress resilience? A 2026 Frontiers in Nutrition crossover trial offers signal in the affirmative. Small at 16 participants, but the data showing PEA 600mg for 6 weeks raised autonomic resilience quantitatively carries weight.

Trial design

A double-blind, placebo-controlled crossover trial in 16 female university students.

Participants: female university students at moderate stress (Perceived Stress Scale criteria)
Intervention: Levagen+ 700mg (containing 600mg PEA) or placebo
Duration: 6 weeks + 6-week washout + 6 weeks crossover
Measures: HRV (SDNN, RMSSD), salivary cortisol, self-reported stress, mood

Crossover design controls for individual variation since each participant experiences both interventions, strengthening effect comparison.

Key result: SDNN shift

The clearest result was SDNN.

PEA group: SDNN +9.70 ± 6.02 ms (increase)
Placebo group: SDNN -5.72 ± 3.14 ms (decrease)
Statistical significance: p = 0.024

The directionality matters. Placebo group autonomic resilience actually declined during the trial period (academic stress accumulating), while PEA group resilience improved in the same environment. The same external stress produced opposite autonomic responses in the two arms.

Other markers unchanged

Notably, other markers didn’t reach statistical significance.

Salivary cortisol: no significant change
Self-reported stress (PSS): trended down but not significant
Self-reported mood (POMS): no change
Other HRV measure (RMSSD): trended but not significant

This pattern matches PEA’s mechanism. PEA produces resilience through autonomic parasympathetic activation, not by directly altering stress hormones (cortisol) or subjective cognition. Objective physiological markers shift while perceived stress intensity may not change much.

How PEA works

PEA (palmitoylethanolamide) is a fatty acid amide the body produces. First isolated in 1957, used in clinical pain management since the 1990s. Mechanisms.

PPAR-α nuclear receptor activation: anti-inflammation, neuroprotection
Mast cell stabilization: allergic and inflammatory response suppression
Indirect endocannabinoid modulation: doesn’t bind CB1/CB2 directly but slows degradation of other endocannabinoids (anandamide), sustaining system activity
Vagus nerve hypothesis: gut-brain axis parasympathetic activation

The trial’s SDNN improvement aligns most cleanly with the vagus/parasympathetic pathway.

Small sample limitation

16-participant crossover trials have limited statistical power. Effect size is clear but reproducibility in different populations (middle-aged, menopausal, different stress contexts) needs verification. Other PEA trials show similar patterns (small sample, clear effect size, only some markers significant), so the next step is 100-participant-scale RCTs to strengthen power.

PEA’s expanding indications

The interesting context is PEA expanding beyond pain.

Neuropathic and chronic pain: thickest evidence (1990s onward)
Menstrual pain: women-specific data accumulating
Respiratory infection recovery: trials in progress
Post-exercise knee pain: PlexoZome Levagen post-exercise RCT
Cognition (students): Levagen+ student cognitive trial
Stress resilience (female students): this trial

The same compound producing effects across multiple domains stems from PEA’s multi-layer mechanism. PPAR-α activation affects nearly all tissues.

Korean market position

In Korea, PEA is classified as a general dietary supplement, not MFDS health functional food certified. Pain-domain pharmaceutical PEA requires prescription, but general dietary supplement PEA is available via direct import or select specialty stores. Levagen+ is Gencor’s branded PEA ingredient from Australia, with PlexoZome (enhanced absorption) form also available.

Direct-import monthly cost: 40,000-70,000 KRW; PlexoZome form 60,000-120,000 KRW. Beyond standalone PEA, combination products with magnesium, L-theanine, and tongkat ali for stress and sleep are increasingly common.

What to verify

When using PEA supplements.

Evidence tier: pain (thick) > stress/sleep (accumulating) > cognition (early)
Sample limits: small trials predominate, individual variation in effect size
Absorption form: micronized or PlexoZome forms have higher bioavailability than plain PEA
Drug interactions: PPAR-α activity may affect some drug metabolism; consult prescriber if on medications
Pregnancy/breastfeeding: limited safety data, generally avoided

What’s next

PEA’s position in the supplement market is expanding rapidly. From 1990s pain pharmaceutical, to 2010s dietary supplement entry, to late-2020s expansion into stress, sleep, and women’s health. Next-generation 100-500 participant RCTs will refine the prescription/non-prescription boundary, and Korean MFDS health functional food certification is expected to be considered.

Source: Frontiers in Nutrition / PMC